Company / Total Assets
Rein Therapeutics, Inc. Total Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$24.2M
FY2025
5-year range
$22.0M / $106.0M
FY2021-FY2025
Trend
-61.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 9 years, ranging from $16M in FY2020 to $106M in FY2023.
Based on SEC 10-K filings.
$24M in FY2025 with a 5-year CAGR of +8.1%.
Declined from $106M to $24M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- +3.2%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +8.1%, indicating consistent growth.
- In FY2025, total assets decreased 61.2% year-over-year.
- Peak total assets was recorded in FY2023.
- Lowest total assets in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.2M | -61.2% |
| FY2024 | $62.2M | -41.3% |
| FY2023 | $106.0M | +381.7% |
| FY2022 | $22.0M | -54.6% |
| FY2021 | $48.5M | +196.7% |
| FY2020 | $16.3M | -38.3% |
| FY2019 | $26.5M | -12.7% |
| FY2018 | $30.3M | -42.5% |
| FY2017 | $52.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026